Entegre Genetik, Moleküler ve Giyilebilir Sensör Biyobelirteçleri, Bayesian Makinesinin Parkinson Hastalığında Öğrenmeye Dayalı Hassas Stratifikasyonunu Etkinleştirir: Kapsamlı Bir Çok Kohort Doğrulama Çalışması

Araştırma özeti

Aşağıdaki metin kaynak makalenin lisansı doğrulanmış orijinal özetidir. cc0

We present a Bayesian machine learning framework integrating genetic, molecular, and wearable sensor biomarkers for precision medicine in Parkinson’s disease. Using PPMI (4,775 patients, 14,473 longitudinal records) and LRRK2 Consortium (627 individuals, 2,958 biological specimens), we demonstrate: (1) LRRK2 G2019S confers 1.92-fold PD risk (individual-level χ 2 = 36.6, p = 1.4 × 10 − 9 ; sex-adjusted OR=2.73) with carriers exhibiting 4.35-point higher motor severity (95% CI [1.95, 6.47], rank-biserial r = −0.270); (2) Wearable IMU sensors quantified Arm Swing Asymmetry (27% prevalence, n = 178) and Dual-Task Cost (14.87% degradation, t = 14.98, p < 0.001), enabling continuous cognitive-motor network monitoring; (3) Molecular markers phospho-LRRK2 ( n = 884) and CSF ε -synuclein seed amplification ( n = 145) provide therapeutic monitoring and differential diagnosis; (4) Prodromal screening identified olfactory dysfunction (50.2%, n = 5, 122) and RBD (37.5%, n = 1, 548). Bayesian clustering via Evidence Lower Bound selection achieved Silhouette=0.535 with bootstrap stability (Jaccard=0.769), outperforming alternatives (0.170–0.452). Risk prediction model: AUC=0.717, calibration slope=1.197. This reproducible framework (complete code-result traceability, TRIPOD+AI compliant) enables mechanism-targeted precision medicine aligned with SDGs 3, 9, 10.

İlgili konular